Global Stem Cells Group to Develop New Stem Cell Therapy for Neurodegenerative Disease

Global Stem Cells Group Inc. (GCSG) plans to collaborate with regenerative medicine specialist Burton Feinerman, M.D., to offer new stem cell therapies that combine adult stem cells derived from adipose tissue, bone marrow and peripheral blood with differentiated cells and transference factors, using patented protocols developed by Feinerman.

The treatment protocols will target specific neurodegenerative conditions that primarily affect the neurons in the brain. Neurons are critical components of the nervous system, which includes the brain and spinal cord. When they become damaged die, neurons don’t reproduce or replace themselves. Examples of neurodegenerative diseases include Alzheimer’s and Parkinson’s disease.

Neurodegenerative diseases are incurable and debilitating conditions that lead to the progressive degeneration or death of nerve cells, causing difficulty with movement or mental function (dementia). According to a March 2015 World Health Organization report, dementias are responsible for the greatest burden of disease with Alzheimer’s representing approximately 60-70 percent of cases.

Feinerman is a physician and research scientist specializing in stem cell therapies, ant-aging medicine and gene therapies to treat a variety of conditions and diseases. He is a member of the GSCG Advisory Board.

GCSG is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. The company is based in Miami Lakes, Fla.